Triglav Skladi D.O.O. Has $12.51 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Triglav Skladi D.O.O. increased its stake in Thermo Fisher Scientific Inc. by 3.5%, bringing its total holdings to $12.51 million, making it the firm's 24th largest investment.
• CEO Marc N. Casper sold 8,000 shares of the company, resulting in a 6.49% decrease in his ownership, while insiders sold a total of 18,400 shares over the last three months.
• Thermo Fisher Scientific's recent financial results showed a revenue of $10.86 billion and earnings per share of $5.36, exceeding analyst expectations and marking a 2.9% increase compared to the same quarter last year.

Triglav Skladi D.O.O. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 25,145 shares of the medical research company's stock after acquiring an additional 840 shares during the period. Thermo Fisher Scientific comprises 1.1% of Triglav Skladi D.O.O.'s investment portfolio, making the stock its 24th biggest position. Triglav Skladi D.O.O.'s holdings in Thermo Fisher Scientific were worth $12,512,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cypress Advisory Group LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $253,000. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares in the last quarter. Deutsche Bank AG lifted its stake in Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after purchasing an additional 114,277 shares in the last quarter. Hancock Whitney Corp raised its position in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after buying an additional 30 shares in the last quarter. Finally, Cetera Trust Company N.A raised its position in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after buying an additional 150 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,340,824.30. This represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,400 shares of company stock worth $8,345,792. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 3.4%

Shares of TMO stock opened at $477.92 on Wednesday. The stock has a market cap of $180.47 billion, a P/E ratio of 27.64, a PEG ratio of 2.47 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company's fifty day simple moving average is $429.68 and its two-hundred day simple moving average is $461.95.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.